Auriga Maintains a 'Hold' on Heartware Int'l (HTWR); Enrollment Completed for ENDURANCE Trial
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga maintains a 'Hold' on Heartware Int'l (NASDAQ: HTWR) price target of $73.00.
Analyst, Peter McDonald, said, "Last night, HeartWare announced it has completed enrollment in the 450 patient ENDURANCE trial. The trial is a head-to-head comparison of HTWR's HVAD and Thoratec's (Nasdaq: THOR)(Hold) Heartmate II. In addition, HTWR is applying for a Continued Access Protocol (CAP) in the U.S., which would allow the 50 centers involved in the trial to implant a limit number of implants. Both the timing and CAP application is in-line with our expectations. The primary endpoint of the non-inferiority trial is survival at two years, and secondary endpoints include adverse events (such as bleeding and infection), functional status, hospitalization, neuro-cognitive function and quality of life. HTWR has the ability to analyze the data once the 300th patient reaches the two year post-implant time point. As a reminder, HTWR had 311 patients implanted as of the end of 2011, suggesting the first data from ENDURANCE could be available in early 2014. ENDURANCE enrollment right on track. The ENDURANCE trial is a randomized, controlled, unblinded trial that enrolled 450 patients at 50 clinical sites and began in June 2010."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $77.82 yesterday.
Analyst, Peter McDonald, said, "Last night, HeartWare announced it has completed enrollment in the 450 patient ENDURANCE trial. The trial is a head-to-head comparison of HTWR's HVAD and Thoratec's (Nasdaq: THOR)(Hold) Heartmate II. In addition, HTWR is applying for a Continued Access Protocol (CAP) in the U.S., which would allow the 50 centers involved in the trial to implant a limit number of implants. Both the timing and CAP application is in-line with our expectations. The primary endpoint of the non-inferiority trial is survival at two years, and secondary endpoints include adverse events (such as bleeding and infection), functional status, hospitalization, neuro-cognitive function and quality of life. HTWR has the ability to analyze the data once the 300th patient reaches the two year post-implant time point. As a reminder, HTWR had 311 patients implanted as of the end of 2011, suggesting the first data from ENDURANCE could be available in early 2014. ENDURANCE enrollment right on track. The ENDURANCE trial is a randomized, controlled, unblinded trial that enrolled 450 patients at 50 clinical sites and began in June 2010."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $77.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
- Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
